In the ASTRO phase 3 abstract, adults with moderately to severely active ulcerative colitis receiving subcutaneous guselkumab induction had a 21 percentage point adjusted advantage over placebo in week 12 clinical remission. ASTRO was a double-blind, treat-through, randomized, placebo-controlled phase 3 trial evaluating subcutaneous induction and maintenance treatment. Week 24 remission was also higher in both guselkumab groups, while the overall safety profile was broadly similar across groups.
Subcutaneous Guselkumab Meets Week 12 Endpoint In Ulcerative Colitis (ReachMD)
0